Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation

Woodbridge, Ontario (ots/PRNewswire) -

Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or
the "Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease ("CVD") and overall
health, announced today that an article entitled, "Redox-sensitive
induction of Src/PI3-kinase/Akt and MAPKs pathways activate eNOS in
response to EPA:DHA 6:1," authored by Faraj Zgheel, Mahmoud Alhosin,
Sherzad Rashid, Mélanie Burban, Cyril Auger and Valérie B.
Schini-Kerthhas been published in the current issue of the scientific
journal PLOS ONE and is available at http://www.plosone.org/article/i
nfo%3Adoi%2F10.1371%2Fjournal.pone.0105102.

The findings of Zgheel et al. demonstrate that the sustained
endothelial vasodilatory effect of Omega-3 formulations are EPA:DHA
ratio and purity dependent and involve predominantly the endothelial
nitric oxide synthase derived nitric oxide formation.

The Pivotal 6:1 EPA:DHA formulation of VASCAZEN(R)was shown to
cause the most pronounced sustained vasodilatory effect when compared
to a 1:1 EPA:DHA, pure EPA or pure DHA. The study published by the
researchers of the University of Strasbourg, France, is the first to
demonstrate that the biological activity of Omega-3 formulations is
not linked to either the ratio or the purity alone but depends on the
interplay of the components of each respective formulation.

"The significance of these results emphasizes not only the
superior sustained endothelial vasodilatory profile of Pivotal's
VASCAZEN(R), but also points to its beneficial effects in Omega-3
deficient individuals," said Dr. George Jackowski, Chief Scientific
Officer. "We are very excited that the VASCAZEN(R) formulation was
superior to the other existing commercial products in the marketplace
in terms of sustained coronary vasodilation (i.e. increase of blood
flow) which is important for patients with Coronary Heart Disease who
have compromised coronary vessels."

About PLOS ONE

PLOS ONE publishes primary research from all areas of science and
employs a combination of peer review and post-publication rating and
commenting, to maximize the impact of every report it publishes. We
are published by the Public Library of Science (PLOS), the
open-access publisher whose goal is to make the world's scientific
and medical literature a public resource. All works published in PLOS
ONE are Open Access.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO),
specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics' lead product
VASCAZEN(R) is a prescription only medical food formulated to meet
the dietary Omega-3 deficient needs of patients with cardiovascular
disease through elevating Eicosapentaenoic acid (EPA) and
Docosahexaenoic acid (DHA) to levels associated with reduced risk of
cardiovascular complications. OMAZEN(R)is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN(R) is a patented product available
for sale and distribution in Canada.

About VASCAZEN(R)

VASCAZEN(R) is currently available in the U.S. as a prescription
only medical food specifically formulated for the dietary management
of an Omega-3 deficiency in cardiovascular patients. VASCAZEN(R) is a
>90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN(R) has been clinically shown to correct an Omega-3
deficiency within eight weeks of treatment with positive concomitant
effects on the lipid profiles, mainly a 48% reduction of
triglycerides and an increase of HDL without negative impact on the
LDL-C lipid profile. VASCAZEN(R)'s results were achieved with a dose
of 3 grams of EPA and DHA per day of a prescription grade, high
purity, uniquely formulated Omega-3.

Disclosure Notice

The information contained in this document is as of August 19,
2014. This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by the
use of words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe", "project",
"potential", and similar expressions with any discussion of future
operating or financial performance or events. In particular, factors
that could cause actual results to differ materially from those in
forward looking statements include the following: Pivotal's inability
to obtain additional financing on acceptable terms; growth in costs
and expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as of
the date made and are not guarantees of future performance. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result of
new information or future events or developments. The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.

For further information:

Company Contacts:
Kristine DiMatteo
Communications and Public Relations Manager
Phone: +1-905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

Investor & Media Contact:

Stephen Kilmer
President, Kilmer Lucas Inc.
Phone: +1-647-872-4849
E-Mail: stephen@kilmerlucas.com

ots Originaltext: Pivotal Therapeutics Inc
Im Internet recherchierbar: http://www.presseportal.de